Obtaining approval from the U.S. Food and Drug Administration (FDA) for a key medication can be a huge catalyst for a healthcare stock. It opens up new growth opportunities for the business. And investors become more bullish about its long-term prospects, and the potential the stock has to rise higher in value.
Vertex Pharmaceuticals Incorporated VRTX reported mixed results for its fourth quarter on Monday. The company posted quarterly adjusted earnings of $3.48 per share which missed the analyst consensus estimate of $4.03 per share. The company reported quarterly sales of $2.912 billion which beat the analyst consensus estimate of $2.781 billion.
In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against other Renaissance Technologies portfolio’s top stock picks. The American ...
Barclays raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $467 from $435 and keeps an Equal Weight rating on the shares. The company reported a modest beat in Q4 and in-line ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results